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Abstract
Background: Exercise testing to aid diagnosis of exercise-induced bronchoconstriction (EIB) is commonly
performed. Reproducibility of the airway response to a standardized exercise protocol has not been reported in
subjects being evaluated with mild symptoms suggestive of asthma but without a definite diagnosis. This study
examined reproducibility of % fall in FEV1 and area under the FEV1 time curve for 30 minutes in response to two
exercise tests performed with the same intensity and duration of exercise, and inspired air conditions.
Methods: Subjects with mild symptoms of asthma exercised twice within approximately 4 days by running for
8 minutes on a motorized treadmill breathing dry air at an intensity to induce a heart rate between 80-90%
predicted maximum; reproducibility of the airway response was expressed as the 95% probability interval.
Results: Of 373 subjects challenged twice 161 were positive (≥10% fall FEV1 on at least one challenge). The EIB was
mild and 77% of subjects had <15% fall on both challenges. Agreement between results was 76.1% with 56.8% (212)
negative (< 10% fall FEV1) and 19.3% (72) positive on both challenges. The remaining 23.9% of subjects had only one
positive test. The 95% probability interval for reproducibility of the % fall in FEV1 and AUC0-30 min was ± 9.7% and ±
251% for all 278 adults and ± 13.4% and ± 279% for all 95 children. The 95% probability interval for reproducibility of
%f a l li nF E V 1 and AUC0-30 min for the 72 subjects with two tests ≥10% fall FEV1 was ± 14.6% and ± 373% and for the
34 subjects with two tests ≥15% fall FEV1 it was ± 12.2% and ± 411%. Heart rate and estimated ventilation achieved
were not significantly different either on the two test days or when one test result was positive and one was negative.
Conclusions: Under standardized, well controlled conditions for exercise challenge, the majority of subjects with
mild symptoms of asthma demonstrated agreement in test results. Performing two tests may need to be
considered when using exercise to exclude or diagnose EIB, when prescribing prophylactic treatment to prevent
EIB and when designing protocols for clinical trials.
Background
Exercise is a widely recognised stimulus for provoking
transient airway narrowing. Exercise-induced broncho-
constriction (EIB) is the term used to describe this phe-
nomenon. The most commonly used measure to express
severity of EIB is the post-exercise fall in forced
expiratory volume in one second (FEV1), as a percentage
of the pre-exercise value [1]. A ≥10% fall in FEV1 is
reported to provide the best discrimination between asth-
matic and normal responses in laboratory based running
tests [2]. It is also the value suggested as the cut off for a
positive test in the ATS and ERS guidelines for testing
for EIB [3,4]. A second index of EIB severity is the area
under the % fall in FEV1 time curve (AUC0-30 min), which
summarizes the extent and duration of bronchoconstric-
tion. This second index is used to assess the benefit of
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than their benefit on the immediate post exercise fall in
FEV1 [5]. The AUC0-30 min reflects the contribution of
the numerous mediators involved in EIB [6,7].
EIB commonly occurs in people with clinically recog-
nized asthma [8] and has been reported in school chil-
dren, elite athletes, and military recruits without other
clinical signs and symptoms of asthma [9-11]. EIB is
often the first indication of asthma [12] so it is important
to diagnose and then treat underlying asthma recognized
by exercise intolerance. We recently studied and reported
a large number of adults and children with signs and
symptoms suggestive of asthma but without a definitive
diagnosis [13]. The study investigated sensitivity and spe-
cificity of airway responsiveness to methacholine and
mannitol to identify EIB and a physician diagnosis of
asthma [13]. The study examined duplicate controlled
exercise challenges in 373 subjects and the data provided
an opportunity to examine reproducibility of the airway
response to exercise in the type of individual most likely
to be referred for exercise testing for EIB.
Exercise testing to identify EIB in the laboratory is
affected by the type of exercise, intensity and duration
of exercise, inspired air conditions, baseline lung func-
tion and time since last medication or exercise. This
paper reports the reproducibility of the % fall in FEV1
and AUC0-30 min in response to an exercise protocol
that carefully controlled these variables.
Methods
Subjects: Inclusion/Exclusion Criteria
Subjects were enrolled if they were aged 6-50 years with
a BMI of <35, and reported signs and symptoms sugges-
tive of asthma according to the National Institute of
Health (NIH) Questionnaire [14]. They were required to
have an FEV1 ≥70% of the predicted value at the Screen-
ing Visit [15,16]. Subjects were required to have a
National Asthma Education and Prevention Program
(NAEPPII) asthma severity score of Step 1 with neither
a firm diagnosis of asthma nor an exclusion of the diag-
nosis of asthma. Step 1 of NAEPPII is the mildest and is
defined as symptoms ≤2 times per week, asymptomatic
and normal peak expiratory flow measurements between
exacerbations, exacerbations from only a few hours to a
few days, night time symptom frequency of ≤ 2t i m e s
per month, FEV1 or PEF ≥80% predicted and PEF varia-
bility ≤20%.
Subjects were excluded from participation if they: had
any known other pulmonary disease; had smoked more
than 1 cigarette per week within the past year or had a
≥10 pack year smoking history; had a respiratory tract
infection within the previous 4 weeks; had been skin
test positive to aeroallergens that were present in the
environment during the time of enrolment and reported
worsening of symptoms when exposed to these aero-
allergens during the study; had been diagnosed at the
Screening Visit as definitively (95 to 100% likelihood)
having or not having asthma; had clinically significantly
abnormal chest x-ray or ECG; or had failed to observe
washout time of medications that would interfere with
exercise (including, but not limited to, no use of corti-
costeroids within 4 weeks of the Screening Visit).
The disposition of the study population is given in
Figure 1. The data presented are from the 375 subjects
in the per protocol population that included all subjects
with no major protocol violations previously reported
[13]. Of the 375 subjects, two completed only one exer-
cise challenge leaving 373 who completed two exercise
tests; there were 95 children and 278 adults.
Procedures
The protocol was approved by institutional review boards
and performed at 25 sites in the USA. Each subject or
parent gave written informed consent or assent for min-
ors <18 years of age. At screening the following were
assessed: eligibility; demography; medical history; medi-
cations; spirometry with reversibility (following 360 mcg
of albuterol/salbutamol from a pressurised metered dose
inhaler); and allergy skin-prick testing to 10 common
allergens (positive test taken as a wheal size ≥3m m
of the control). The NIH NAEPPII Questionnaire was
administered and a score was assigned.
Exercise was performed on two separate occasions
beginning 1 - 4 days after the screening visits and within
2 hrs of the same time of day. Medication withholding
was confirmed (Table 1), and spirometry was measured
to determine consistency with values obtained at screen-
ing as previously described [13]. The exercise was per-
formed on consecutive visits (2 and 3) with the second
challenge being in 1 - 4 days after the first. FEV1 needed
to be >70% predicted and within 15% of FEV1 at screen-
ing in order for an exercise challenge to be performed.
Exercise protocol
Exercise was performed by running on a motorized tread-
mill while breathing medical grade dry air (20-25°C) from
a reservoir (Douglas Bag) via a two-way non-rebreathing
valve [17]. Subjects began by walking then running with
the treadmill speed at 2.5 mph with 2.5% incline. Speed
and incline were increased over 2 minutes so that heart
rate (HR) reached 80-90% of predicted maximum (220-
age) and then was maintained for 6 minutes for a total
duration of 8 minutes. This intensity aimed to achieve a
ventilation rate between 14 and 21 times FEV1 L values
that represent between 40 and 60% of maximum predicted
ventilation (35 × FEV1) [18]. The challenge could
be stopped at any time. HR was monitored during and for
30 min after exercise.
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FVC) was measured 5, 10, 15, and 30 minutes after
exercise. The % fall in FEV1 was calculated by subtract-
ing the lowest value recorded after exercise taking the
best of two acceptable attempts at each time point, from
the value measured immediately before exercise,
expressed as a percentage of the pre-exercise value.
Values were not rounded; a 9.99% fall was considered
negative. A subject was deemed positive if there was a
fall of ≥10% in FEV1 at one time point on at least one
of the two exercise challenges [3,4]. Values are reported
as mean and standard deviation (SD). Values for FEV1
post-exercise that remained higher than the pre-exercise
value were censored as 0% falls. The AUC0-30 min was
calculated by the trapezoidal method [19] and expressed
as % fall in FEV1 min
-1.
Spirometry data were captured by using ClinDataLink®
(CDL) (CompleWare Corporation, North Liberty, IA)
and met or exceeded the requirements proposed by
American Thoracic Society/European Respiratory
Figure 1 Subject Disposition. Reproduced from Respiratory Research 2009, 10:4 (23 January 2009) with the permission of the authors.
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each day at three flow rates before use. WebCDL® soft-
ware displayed an electronic record of the volume-time
curves, flow-volume displays, and flow-time displays.
An estimate was made of ventilation in the 2
nd and 6
th
minutes of exercise based on the relationship between
speed and incline of treadmill and oxygen consumption
in ml [21]. The ventilatory equivalent was estimated as
2 7Lp e rLo fV O 2 [22], and ventilation was expressed
as % of maximum voluntary ventilation (MVV). The
estimate of oxygen consumption in mls was:
1.262*weight*(3.5 + (5.36*speed) + (0.24*speed*-
incline)) for running
1.262*weight*(3.5 + (2.68*speed) + (0.48*speed*-
incline)) for walking.
Weight is expressed in kilograms and speed is
expressed in miles per hour. Three miles per hour was
taken to be running.
Statistical Analysis
Reproducibility of the exercise test response was illu-
strated using a Bland-Altman-type plot [23] and calcu-
lated using the method of Chinn [24]. In brief, the
standard deviation of a single measurement was calcu-
lated by dividing the standard deviation of the differences
in % fall in FEV1 values between the two tests (i.e. 7.6 for
the whole group) by the square root of 2 giving a 5.4%
fall, from which we calculated a 95% probability interval
of ± 10.8%. This interval defines a 95% probability that
the difference between any single measurement and the
true value for the subject is within that range. This gives
information about variability of the response that can be
expected in an individual with repeated testing.
Results
Demography
For the per protocol population (n = 375): females com-
prised 51.5%; subjects were 76.3% Caucasian, 8.3% Hispa-
nic and 8.5% Black; subjects had near-normal baseline
spirometry (Table 2); and 7.2% responded positively to a
bronchodilator with ≥12% and ≥200 ml increase in FEV1
above baseline. The characteristics of the 95 children and
278 adults are summarised in Table 2. The mean NAEP-
P I Ia s t h m as c o r ew a s1 . 2 2( S D0 . 5 2 )f o rt h ea d u l t sa n d
1.21 (0.48) for the children. Positive skin tests to at least
one allergen were seen in 78% of the adults and children.
Reproducibility of the Response
The 373 subjects who completed two exercise challenges
did so within 2.6 ± 3.2 (median 2) days. The agreement
Table 1 Required medication withholding periods for medications before exercise tests
Factor Withholding
Period
Inhaled agents Short acting bronchodilators (isoproterenol, isoetharine, metaproterenol, albuterol, levalbuterol, terbutaline)
(e.g. Proventil® or Ventolin®)
8h r
Inhaled anticholinergics or combination products (e.g. Atrovent® or Combivent®) 1 week
Long acting inhaled bronchodilators (salmeterol, formoterol) (e.g. Serevent® or Foradil®) 2 weeks
Inhaled corticosteroid/long acting inhaled bronchodilator combination (e.g. Advair®) 4 weeks
Oral
bronchodilators
Theophylline 24 hr
Intermediate theophylline 48 hr
Long acting theophylline 48 hr
Standard b-agonist tablets 24 hr
Long acting b-agonist tablets 48 hr
Corticosteroids There is no washout for topical corticosteroids applied to skin unless they are high potency steroids 4 weeks
Other
medications
Hydroxyzine, cetirizine (and other antihistamines) 72 hr
Tiotropium bromide 72 hr
Nasals corticosteroids 1 week
b-blockers 1 week
Cromolyn sodium 2 weeks
Nedocromil 2 weeks
Leukotriene modifiers 6 weeks
Foods Coffee, tea, cola drinks, chocolate (caffeinated foods) 12 hr
Strenuous exercise or exposure to cold air to a level that would be expected to interfere with challenges 12 hr
Tobacco 6h r
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tive and 19.3% (72) positive on both challenges.
Seventy-two, 34, and 19 of the 373 subjects had FEV1
falls of ≥10%, ≥15% ≥20%, respectively on both exercise
challenges.
The reproducibility (95% probability value) of the % fall
in FEV1 and the AUC % fall in FEV1 min
-1 for the whole
group and for adults and children separately are given in
Table 3, together with mean and highest falls in FEV1.
The variation for the response in all the adults and all the
children is illustrated in Figures 2 and in Figures 3a and
3b for those with ≥10% fall in FEV1 on both tests.
The reproducibility of the exercise response in relation
to the different NAEPPII scores is given in Table 3.
There was no relationship between the NAEPII score
and the severity of the response to exercise expressed as
the % fall in FEV1 after exercise (Figure 4).
Exercise Response
Post-exercise, 163 of the 375 subjects had ≥10% fall in
FEV1 (mean % fall ± SD was 19.1% ± 9.25 or 610 ±
330 ml) after at least one exercise challenge with 86
having ≥ 15% and 56 ≥ 20% fall in FEV1. Those 77 with
very mild EIB i.e. 10 to 15% fall in FEV1 had a mean fall
of 12.3% ± 1.5 or 395 ± 116 ml. The distribution of the
values for the maximum % fall in FEV1 i sg i v e ni nF i g -
u r e5 .O ft h e1 6 3s u b j e c t s ,1 6 1c o m p l e t e dt w oe x e r c i s e
challenges with 88 having a fall in FEV1 of ≥10% at two
or more time points after exercise and 157 having a fall
in FEV1 ≥ 200 ml (median 530 ml). On the first exercise
challenge 119 had ≥10% fall in FEV1;6 7h a d≥15% fall
in FEV1.O ft h o s e2 7w i t ha≥12% and 200 ml after
bronchodilator, 10 were positive to and 7 were negative
to both exercise challenges, and 10 were positive to only
one challenge.
There were 89 subjects who had a positive test on
only one of two challenges; 45 on the first challenge and
44 on the 2
nd challenge (Figure 6a). For the 89 the
mean difference in FEV1 between the positive and nega-
tive test result was 308 ± 173 ml. For the 44 of 161 sub-
jects identified as positive with a fall in FEV1 ≥10%, only
on the second challenge, 39 (89%) had a fall in FEV1
≤16% and only three subjects had a fall in FEV1 > 20%.
Fifty-five of the 373 subjects had only a rise in FEV1
from baseline on the 1
st c h a l l e n g e ;o n l y7o ft h e s e5 5
subjects had ≥10% fall in FEV1 on the 2
nd challenge.
The mean values for % fall in FEV1 for adults and
children and for those with two negative (< 10% fall),
two positive (≥10% fall) and one positive and one nega-
tive test on each occasion are illustrated Figure 6a.
AUC0-30 min associated with these % falls in FEV1 is
given in Figure 6b. There was no significant difference
in the response to exercise between adults and children.
There was a significant correlation between the maxi-
mum % fall in FEV1 and the corresponding ‘maximum’
AUC0-30 min (r = 0.87, p < 0.001).
Work Load
The exercise load was similar on both tests days. Exer-
cise resulted in a HR, % predicted maximum at 2 and
6 minutes of 82.1% ± 5.6 and 86.6% ± 8.9 on Day 1 and
of 81.5% ± 6.7 and 89.9% ± 6.5 on Day 2 in adults
(p = NS) and 81.9% ± 5.7 and 85.9% ± 10.3 on Day 1
and 81.8% ± 6.3 and 86.7% ± 4.9 on Day 2 in children
(p = NS). There was no significant difference in the esti-
mated ventilation expressed as a % of maximum volun-
tary ventilation between Days 1 and 2 for either the
adults (Day 1 at 2 min 56.8% ± 15.3 and Day 2 58.0% ±
15.2) and children (Day 1 at 2 min 54.7% ± 13.1 and
Day 2 56.3% ± 11.9).
Table 2 Anthropometric data, forced expiratory volume in one second, and smoking history in the per protocol
population
Children
N = 95 Age (yr) BMI FEV1 (L) % Pred FEV1 % Rise Post BD FEV1 (L) Pack Yrs
N=1
Ht (cm) Wt (kg)
Mean 13.0 21.5 2.83 94.2 6.9 0.43 157.6 54.9
SD 3.0 4.3 0.92 12.5 12.8 16.7 18.2
Range 6-17 13.4-33.1 1.15-5.15 63.7-127.4 0-115 118-192 20-102
Median 14 21.3 2.69 92.2 4.4 158 54.9
Adults
N = 278 Age (yr) BMI FEV1 (L) % Pred FEV1 % Rise Post BD FEV1 (L) Pack Yrs
N=4 4
Ht (cm) Wt (kg)
Mean 28.2 25.3 3.49 93.4 5.1 3 170.7 74.2
SD 8.8 4.1 0.71 10.2 5.8 2.9 9.7 15.7
Range 18-50 14.7-34.9 1.97-5.62 70.3-140.1 0-51.5 0-9 150-204 38-135
Median 25 25.0 3.38 93.3 3.99 2.5 170 72.3
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predicted maximum at 2 and 6 minutes on the day of
the highest percent fall in FEV1 of 82.0% ± 5.0 and
87.4% ± 5.0 in adults, and 82.4% ± 5.1 and 86.9% ± 5.1
in children.
The distribution of the estimated ventilation as % of
MVV during the exercise is shown in Figure 7. The
mean estimated ventilation calculated as a percent of
maximum voluntary ventilation during the 2
nd and 6
th
minute of the exercise with the highest fall in FEV1 was
57.3% ± 14.5 and 53.1% ± 12.9 for adults and 54.6% ±
12.9 and 51.1% ± 11.0 for the children. The estimated
ventilation as % of MVV on the 2
nd exercise test showed
a small (+1.21% MVV) though significantly (< 0.009)
higher value compared with the 1
st test for adults and a
small (+1.35% MVV) but not significantly (P < 0.052)
different value for children.
There was no significant difference between the HR %
predicted and estimated ventilation % MVV between the
test on the day the highest % fall in FEV1 was documen-
ted, and on the test on the day the lowest % fall in FEV1
was recorded for the different groups of subjects (data
not shown). There was also no significant difference in
baseline FEV1 % predicted for the two days in the group
where the % falls in FEV1 ≥1 0 %w i t hb o t ht e s t s .T h e
FEV1 % predicted was higher on the day of the highest
%f a l li nF E V 1 for all the other groups; however, the
baseline values for FEV1 % predicted were always above
90% and all the differences were less than 2.4%
predicted.
Discussion
One problem in using an exercise challenge to identify
EIB in the laboratory is ensuring that intensity of
Table 3 Values for the 95% probability interval for % fall in FEV1 and AUC, highest % fall in FEV1, the associated AUC,
mean % fall FEV1 and the SD of the difference between two tests shown for Groups and for different NAEPP values
%Fall
FEV1
AUC % fall FEV1 min
-
1
mean ± SD
Highest
% Fall FEV1
mean ± SD AUC % fall FEV1
min
-1
Mean
% fall FEV1 two
tests
SD
difference
two tests
% fall FEV1
Whole
Group
n = 373
± 10.8% ± 259% 10.95% ± 9.4 -221% ± 221 8.2 7.6
Adults
n = 278
± 9.7% ± 251% 10.4% ± 8.9 -212% ± 214 7.9 6.9
Children
n=9 5
± 13.4% ± 279% 12.6% ± 10.5 -249% ± 239 9.3 9.5
2 tests ≥
10%
n=7 2
± 14.6% ± 373% 24.7% ± 9.7 -525% ± 245 20.8 10.3
2 tests ≥
15%
n=3 4
± 12.2% ± 411% 29.4 ± 8.5 -613% ± 259 25.9 8.6
2 tests ≥
20%
n=1 9
± 14.3 ± 470% 34.0 ± 8.2 -707% ± 246 30.1 10.1
1 test ≥ 10%
n=8 9
± 15.7 ± 370% 14.3 ± 4.8 -289% ± 151 9.4 11.1
2 tests <10%
n = 212
± 5.2% ± 117% 4.9% ± 2.9 -89% ± 75 3.5 3.7
2 tests <
15%
n = 288
± 7.1% ± 168% 6.8% ± 4.2 -132% ± 107 4.9 5.0
NAEPP
Scores
NAEPP = 1
n = 309
±10.7% ± 252% 10.7% ± 9.2 -206% ± 211 8.1 7.5
NAEPP > 1
n=6 4
± 11.4% ± 289% 12.0% ± 10.1 -249% ± 248 9.1 8.1
NAEPP = 2
n=4 8
± 10.3% ± 284% 10.3% ± 8.9 -228% ± 252 7.8 7.3
NAEPP = 3
n=1 6
± 14.6% ± 312% 17.1 ± 11.8 -313% ± 235 12.9 10.3
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Page 6 of 12Figure 2 Reproducibility of the % fall in FEV1 and area under the FEV1 curve following exercise. The difference between values for % fall
FEV1 and AUC0-30 min % fall FEV1 per min on the two exercise challenges in relation to the average value for the two challenges in adults (a and
b) and children (c and d). The interval defines the 95% probability that the difference between a single measurement and the true value for the
subject is within that range.
Figure 3 Reproducibility of the % fall in FEV1 and area under the FEV1 curve following exercise in subjects positive on both occasions.
The difference between values for a) % fall in FEV1; and b) AUC0-30 min on the two challenges in relation to the average value on the two
challenges for those who had a fall in FEV1 ≥10% on both challenges. The interval defines the 95% probability that the difference between a
single measurement and the true value for the subject is within that range.
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air are controlled and are adequate for eliciting the EIB
response. In this multicentre study exercise duration
was 8 minutes, inspired air was dry, and intensity of
exercise was sufficient for HR to reach the value
required by the protocol, i.e. 80-90% predicted maxi-
mum by the 2
nd minute of exercise and HR was not sig-
nificantly different on the two test days. Appropriate
times for withdrawal of medications were verified and
pre-exercise FEV1 was >70% predicted in all but 2 sub-
jects (both children) and it was similar on both occa-
sions (and was actually greater than a mean of 90%). No
subject had taken inhaled corticosteroids within the last
4 weeks, or long or short- acting beta2 agonist for
48 hours or 8 hours, respectively. Minimising the differ-
ence in these variables between tests allowed us to
examine the natural variation of the airway response
within a few days. We used one time point ≥10% fall to
identify a positive test because this has been common
practice. However we allowed a period of 5 minutes for
recovery before the first FEV1 was measured. We
excluded those who were symptomatic to the allergens
to which they tested positive to a skin test at the time
to reduce variability due to environmental factors. We
are unaware of any other study that has given this level
of attention to variables when performing two exercise
challenges to identify EIB. Knowledge about normal var-
iation in the exercise response is critically important
when interpreting a negative test or when evaluating an
exercise response to a therapeutic agent.
The ventilation reached and sustained during exercise
is a primary determinant of the % fall in FEV1 [4]. How-
ever equipment for measuring ventilation during exer-
cise is expensive and heart rate has been preferred to
confirm the intensity of exercise in the United States of
America. To ensure that subjects reached the minimum
ventilation (40% of MVV recommended by other proto-
cols [4]) we made an estimate of oxygen consumption
from the speed and slope of the treadmill and the
weight of the subject protocols and assumed a ventila-
tory equivalent of 27L of ventilation per L of VO2 using
published equations [4]. This target ventilation was
achieved between by the 2
nd minute of exercise and
MVV exceeded 50% in the majority of adults and chil-
dren. While a direct measurement of ventilation would
have been preferable the estimated values, based on the
work load and expressed as a % MVV, at 2 min and
Figure 4 %f a l li nF E V 1 in relation to NAEPPII severity score.
Individual values for the maximum % fall in FEV1 after exercise in
relation to the NAEPPII severity grading for asthma.
Figure 5 Distribution of the maximum % fall in FEV1. Distribution of the highest % fall in FEV1 after exercise challenge in 375 subjects.
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Page 8 of 12Figure 6 %f a l li nF E V 1 and AUC on the two exercise tests. The mean and standard deviation for:- a) average % fall FEV1 on exercise; b)
average AUC0-30 min FEV1 in 373 subjects and for 278 adults and 95 children. The groups are:- those negative, <10% fall in FEV1 after exercise,
those negative/positive and positive/negative on the 1
st and 2
nd challenge, and those with two positive challenges, i.e. ≥10% fall in FEV1.
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Page 9 of 126 min were the same as the values measured in adults
during 8 minutes of bicycle exercise [25].
As may have been expected from a group of patients
without a definitive diagnosis of asthma, the response to
exercise, when positive, was mild and 77% of the sub-
jects had a fall in FEV1 < 15% on both exercise chal-
l e n g e s .I no n l y3 4o f1 6 1s u b j e c t sd i da≥15% fall occur
on both exercise challenges, a frequency probably con-
sistent with their mild symptoms and indefinite diagno-
sis of asthma. A fall in FEV1 after exercise of ≥20% is
the value suggested for inclusion in clinical trials to
evaluate a drug for EIB (FDA Guidance for Industry,
http://www.fda.gov./cder/guidance). This value occurred
on two exercise challenges in only 19 of the 161 subjects
(11.8%) with EIB in this study or only in 5.1% of the
subjects who were exercised twice.
For those who had two exercise challenges with falls
greater than 10%, the mean maximum fall after exercise
was 24.7% ± 9.7, leaving little doubt about a diagnosis
of EIB. The reproducibility of the response in this group
was ±14.6% and compares well with the value of ±15.8%
calculated in adults with an established diagnosis of
asthma performing repeated exercise on a cycle
ergometer [25].
We assigned a value of 0% fall for those demonstrating
o n l yar i s ei nF E V 1 in response to exercise; a post-exer-
cise fall is characteristic of asthma while a post-exercise
rise in FEV1 is not and occurs in many non-asthmatic
subjects [26]. The mean maximum fall in FEV1 plus 2SDs
(4.9% ± SD 2.9) for the group with two negative chal-
lenges (e.g. those who had <10% fall in FEV1 on both
challenges) was 10.7% and similar to that reported for
groups of normal adults or children, without a history of
symptoms of asthma, exercising in ambient air in a
laboratory [2,10,27]. Thus, subjects with an NAEPPII
asthma severity score of ≥1 can have a reproducible
response to exercise similar to that of a healthy subject
with no history of asthma
The study results confirm that there is little difference
between adults and children for the indices used to
express EIB and we used a value of 10% in both groups.
However higher cut-off values have been recommended
to identify EIB in children [28,29]. Using the 15% cut
point recommended by Haby [28], the prevalence of EIB
in the children was reduced from 51.5% (49/95) to
28.4% (27/95). We consider that the 5 times difference
i nt h ed e g r e eo fE I Bi nt h o s ew i t h≥10% fall in FEV1
(24.7% ± 9.7) on both occasions and those with ≤10%
fall on both occasions (4.9% ± 2.9) supports the use of a
10% cut-off to include or exclude a definitive diagnosis
of EIB when challenges are repeated over a short period.
We used a cut off point of ≥10% fall in FEV1 to analyse
the AUC0-30 min and its reproducibility. There was also
>5 times difference in the AUC0-30 min between those
with two challenges with ≥10% fall in FEV1 (-525 ± 245%
FEV1 min
-1)c o m p a r e dw i t ht h o s ew i t ht w oc h a l l e n g e s
with <10% fall in FEV1 (-89 ± 75% FEV1 min
-1). Based on
the mean plus 2SDs in those with two challenges with
<10% fall in FEV1, we suggest an upper cut-off value for
AUC0-30 min of 240% fall in FEV1 min
-1 for a negative
test. The utility of having values for the reproducibility of
AUC0-30 min is that there are drugs such as montelukast
that have limited effect on the maximum % fall in FEV1
but have a profound benefit in enhancing recovery of
FEV1 to baseline [5]. In keeping with others [30] who
reported a smaller group of known asthmatic subjects
over a longer period, the values for reproducibility of the
% fall in FEV1 were superior to the AUC0-30 min.
In the 89 subjects positive on only one challenge
(Figure 6) we considered that this variation may have
been due to a change in the intensity of exercise on the
two test days or perhaps other characteristics of this
g r o u p .H o w e v e rt h ev a r i a t i o ni nt h e%f a l li nF E V 1 on
the two test days was not explained by differences in the
ventilation % MVV, HR % predicted maximum. The
FEV1 % predicted was significantly higher (p < 0.02) on
the day of the positive challenge (92.1% ± 11.3) com-
pared with the day of the negative test (90.2% ± 11.1)
although the difference was small. The variability
between a positive and negative test result may be due
to other factors, perhaps environmental or dietary, or
simply the intrinsic reproducibility of the test itself.
The study group had mild symptoms and signs sug-
gestive of asthma but the NAEPPII grading could not be
relied upon either to identify EIB or to predict its sever-
ity or reproducibility of the response. However, the
NAEPPII is a score of asthma severity [14] and does not
necessarily include symptoms provoked by exercise.
This may not be important in that other investigators
who have questioned subjects specifically about exercise
Figure 7 Distribution of the % of maximum voluntary
ventilation during the 6
th minute of exercise. Distribution of the
values estimated for percentage of maximum voluntary ventilation
during exercise test on the test when the highest fall in FEV1 was
measured.
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predictors of either presence or severity of EIB
[10,31,32].
The data presented here are a secondary analysis of a
previously reported study (NCT00252291) [13]. The
protocol required two exercise challenge tests to be per-
formed under the same controlled conditions on conse-
cutive visits prior to a mannitol and a methacholine
challenge. All but two subjects of the 375 in the pre-
viously reported study performed two challenge tests.
For these reasons this study offered an ideal opportunity
to determine reproducibility of the response to exercise
in a large group in an unbiased manner.
The usefulness of these data are not only in under-
standing that more than one test may be required to
exclude a diagnosis of EIB but also in determining the
benefit of treatment or how severe EIB should be for
inclusion in a drug trial. For example the variability in
the % fall in FEV1 as expressed by the 95% probability
value for subjects with two tests ≥2 0 %w a s1 4 . 3 %a n d
t h em e a n%f a l li nF E V 1 was 30.3%. That means that on
a second test a subject with a fall of 30.1% on initial
testing would fall 30.1% ± 14.3% (range 44.4-15.8%) on
a second occasion exercising under identical conditions
within a few days. Thus for a drug to be regarded as
beneficial the % fall would need to be less than 15.8%
on repeated challenge.
In our subjects with mild symptoms of asthma, good
lung function, and a low response rate to bronchodila-
tor, a single exercise test did not rule out mild EIB
and a second exercise test under the same conditions
identified an extra 44 subjects, 27% of the total posi-
tive, with ≥10% fall in FEV1. It is unlikely that repeat
exercise challenge is useful in those recording a rise in
FEV1 on the initial challenge, as the chance of being
positive on the second test was low and, even when
the exercise challenge was positive, the falls in FEV1
were very mild.
Conclusions
The majority of subjects with signs and symptoms sug-
gestive of asthma without a definitive diagnosis will have
the same outcome i.e. positive or negative test result fol-
lowing rechallenge when exercise is standardized for
intensity, duration, and condition of the inspired air.
However a minority will have a positive test result on
o n l yo n ee x e r c i s et e s t .T h e s ed a t aa l s os h o wt h a tf o r
most subjects the EIB will be mild (< 15% fall in FEV1)
and particularly so for those positive on a second chal-
lenge after the first exercise challenge was negative. This
study provides evidence for the degree of variability in
response to duplicate exercise challenges and suggests
that for some subjects with mild symptoms more than
one test may be required before either a diagnosis of
EIB is excluded or prophylactic treatment is prescribed.
Finally, these data in a large number of adults indicate
that the reproducibility of the response in adults is simi-
lar to that observed in children.
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